The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference demonstrate why optimal treatment of...
Esperovax, a leading developer of oral vaccines, announced it has signed a new, exclusive licensing agreement with Innovation Partners at the University of Michigan...
